First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (TRIPLETE)

• ClinicalTrials.gov Identifier: NCT03231722
• Recruitment Status: Completed
• First Posted: July 27, 2017
• Last Update Posted: January 5, 2023
• Sponsor: Gruppo Oncologico del Nord-Ovest
• Information provided by (Responsible Party): Gruppo Oncologico del Nord-Ovest

Tracking Information

• First Submitted Date: July 3, 2017
• First Posted Date: July 27, 2017
• Last Update Posted Date: January 5, 2023
• Actual Study Start Date: September 13, 2017
• Actual Primary Completion Date: June 15, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: July 24, 2017)

Overall response rate [ Time Frame: 12 months ]

the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: July 24, 2017)

• Overall Toxicity Rate [ Time Frame: 24 months ]
  the percentage of patients, relative to the total of enrolled subjects, experiencing any adverse event, according to National Cancer Institute Common Toxicity Criteria (version 4.0)
• Toxicity Rate [ Time Frame: 24 months ]
  the percentage of patients, relative to the total of enrolled subjects, experiencing a specific adverse event of grade 3/4, according to National Cancer Institute Common Toxicity Criteria (version 4.0)
• Progression Free Survival [ Time Frame: 24 months ]
  the time from randomization to the first documentation of objective disease progression or death due to any cause, whichever occurs first. Documentation of disease progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment
• Overall Survival [ Time Frame: 48 months ]
  the time from randomization to the date of death due to any cause
• Centrally assessed Overall response rate [ Time Frame: 12 months ]
  the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria based on central re-evaluation of CT scan images.
• Early Tumour Shrinkage Rate [ Time Frame: up to 2 months from randomization ]
  the percentage of patients, relative to the total of the enrolled subjects, achieving a ≥20% decrease in the sum of diameters of RECIST target lesions at week 8 compared to baseline.
• Deepness of Response [ Time Frame: 12 months ]
  the relative change in the sum of longest diameters of RECIST target lesions at the nadir, in the absence of new lesions or progression of non-target lesions, when compared with baseline.
• R0 Resection Rate [ Time Frame: 12 months ]
  the percentage of patients, relative to the total of enrolled subjects, undergoing secondary R0 resection of metastases

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
• Official Title: The TRIPLETE Study RANDOMIZED PHASE III STUDY OF TRIPLET mFOLFOXIRI PLUS PANITUMUMAB Versus mFOLFOX6 PLUS PANITUMUMAB AS INITIAL THERAPY FOR UNRESECTABLE RAS AND BRAF WILDTYPE METASTATIC COLORECTAL CANCER PATIENTS

Brief Summary

• The association of FOLFOX (5-fluoruracil, folinic acid, and oxaliplatin) and pan is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients.
• The phase III TRIBE trial recently demonstrated that FOLFOXIRI (5-fluoruracil, folinic acid, oxaliplatin and irinotecan) plus bev significantly prolongs PFS and OS and increases RECIST response rate, ETS and DoR, as compared to FOLFIRI (5-fluoruracil folinic acid, and irinotecan) plus bev. The advantage provided by the intensification of the upfront chemotherapy backbone is independent of RAS and BRAF mutational status.
• Some phase II trials recently assessed the safety and activity of the combination of three-drugs chemotherapy regimens with an anti-EGFR monoclonal antibody. Promising activity results in terms of RECIST response rate and R0 resection rate have been achieved, with some safety concerns with special regards to gastrointestinal toxicity.
• In the phase II randomized MACBETH study the combination of a modified schedule of FOLFOXIRI with cetuximab determined remarkable activity results, with an acceptable and manageable safety profile.
• The optimal duration of the upfront treatment with chemotherapy plus anti-EGFRs is not established. The phase II MACRO-2 trial suggested that interrupting FOLFOX after 4 months while continuing cet alone as maintenance, is a reasonable option.
• Activity parameters (RECIST response rate, ETS, DoR) are clinically relevant endpoints, associated with longer survival, in particular with anti-EGFR moAb-based treatment.

On the basis of these considerations, we designed the present phase III randomized trial of first-line mFOLFOXIRI plus pan versus mFOLFOX6 plus pan in RAS and BRAF wt unresectable mCRC patients.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description:

open label

Primary Purpose: Treatment

• Condition: Metastatic Colorectal Cancer

Intervention

• Drug: Panitumumab
  6 mg/kg iv over 60 minutes, day 1
• Drug: Irinotecan
  150 mg/sqm iv over 60 minutes day 1
• Drug: Oxaliplatin
  85 mg/sqm iv over 2 hours day 1
• Drug: l-leucovorin
  200 mg/sqm iv over 2 hours
• Drug: 5-fluorouracil
  400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;

Study Arms

• Active Comparator: mFOLFOX6 + Panitumab
  • Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by
  • Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with
  • L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by
  • 5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by
  • 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice.
  Interventions:

  • Drug: Panitumumab
  • Drug: Irinotecan
  • Drug: l-leucovorin
  • Drug: 5-fluorouracil
• Experimental: mFOLFOXIRI + Panitumumab
  • Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by
  • Irinotecan 150 mg/sqm iv over 60 minutes day 1, followed by
  • Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with
  • L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by
  • 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice.
  Interventions:

  • Drug: Panitumumab
  • Drug: Irinotecan
  • Drug: Oxaliplatin
  • Drug: l-leucovorin
  • Drug: 5-fluorouracil

Publications *

• Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 Sep 1;40(25):2878-2888. doi: 10.1200/JCO.22.00839. Epub 2022 Jun 6.
• Borelli B, Moretto R, Lonardi S, Bonetti A, Antoniotti C, Pietrantonio F, Masi G, Burgio V, Marmorino F, Salvatore L, Rossini D, Zaniboni A, Zucchelli G, Martignetti A, Di Battista M, Pella N, Passardi A, Boccaccino A, Leone F, Colombo C, Granetto C, Vannini F, Marsico VA, Martinelli E, Antonuzzo L, Vitello S, Delliponti L, Boni L, Cremolini C, Falcone A. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 4, 2023): 435
• Original Estimated Enrollment (submitted: July 24, 2017): 432
• Actual Study Completion Date: June 24, 2022
• Actual Primary Completion Date: June 15, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Written informed consent to study procedures and to molecular analyses.
• Histologically proven diagnosis of colorectal cancer.
• Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.
• At least one measurable lesion according to RECIST 1.1.
• Availability of a tumour tissue sample (primary tumour and/or metastatic sites).
• Male or female of 18-75 years of age
• ECOG PS ≤2 for patients aged ≤70 years; ECOG PS 0 for patients aged 71 to 75 years.
• Life expectancy of at least 12 weeks
• Previous adjuvant chemotherapy allowed only if with fluoropyrimidine monotherapy and more than 6 months elapsed between the end of adjuvant and first relapse.
• RAS (codons 12, 13, 59, 61, 117 and 146 of KRAS and NRAS genes) and BRAF (V600E mutation) wt status of primary colorectal cancer or related metastasis (local or central laboratory assessment).
• Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hgb ≥9 g/dl.
• Total bilirubin ≤ 1.5 fold the upper-normal limits (UNL), ASAT (SGOT) and/or ALAT (SGPT) ≤ 2.5 x UNL (or <5 x UNL in the case of liver metastases), alkaline phosphatase ≤ 2.5 x UNL (or <5 x UNL in case of liver metastases).
• Creatinine clearance ≥50 mL/min or serum creatinine ≤1.5 x UNL.
• Male subjects with female partners of childbearing potential must be willing to use adequate contraception - Contraception, starting with the first dose of study therapy through 180 days after the last dose of treatment.

Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

• Women of childbearing potential must have a negative blood pregnancy test at the baseline visit
• Female subjects of childbearing potential must be willing to use an adequate method of contraception - Contraception, for the course of the study starting with the first dose of study therapy through 180 days after the last dose of treatment.

Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

• Will and ability to comply with the protocol.

Exclusion Criteria:

• Previous treatment for metastatic disease.
• Radiotherapy to any site within 4 weeks before the study.
• Previous adjuvant oxaliplatin-containing chemotherapy.
• Previous treatment with EGFR inhibitors.
• Untreated brain metastases or spinal cord compression or primary brain tumours.
• History or evidence upon physical examination of CNS disease unless adequately treated.
• Symptomatic peripheral neuropathy > 1 grade NCIC-CTG criteria.
• Creatinine clearance < 50 mL/min or serum creatinine >1.5 x UNL.
• Clinical signs of malnutrition.
• Neutrophils <1.5 x 109/L, Platelets <100 x 109/L, Hgb <9 g/dl.
• Diagnosis of interstitial pneumonitis or pulmonary fibrosis.
• Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration.
• Clinically significant (e.g. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), serious cardiac arrhythmia requiring medication.
• Treatment with any investigational drug within 30 days prior to enrolment or 2 investigational agent half-lives (whichever is longer)
• Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ.
• Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
• Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness, or hepatitis B or C.
• Definite contraindications for the use of corticosteroids and antihistamines as premedication.
• History of severe allergic reactions or hypersensitivity to trial drugs or any of their excipients.
• Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies.
• Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study and until 180 days after the last trial treatment.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Italy

Administrative Information

• NCT Number: NCT03231722
• Other Study ID Numbers: TRIPLETE
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Gruppo Oncologico del Nord-Ovest
• Original Responsible Party: Same as current
• Current Study Sponsor: Gruppo Oncologico del Nord-Ovest
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Chair: Chiara Cremolini, MD, PhD; U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - Università di Pisa Istituto Toscano Tumori

• PRS Account: Gruppo Oncologico del Nord-Ovest
• Verification Date: January 2023